Bank of America Corp DE Sells 94,006 Shares of LivaNova PLC (NASDAQ:LIVN)

Bank of America Corp DE cut its position in LivaNova PLC (NASDAQ:LIVN) by 16.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 491,089 shares of the company’s stock after selling 94,006 shares during the quarter. Bank of America Corp DE owned about 0.90% of LivaNova worth $22,742,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in LIVN. BNP Paribas Financial Markets grew its holdings in LivaNova by 22.8% in the 4th quarter. BNP Paribas Financial Markets now owns 34,185 shares of the company’s stock valued at $1,583,000 after buying an additional 6,340 shares in the last quarter. Algert Global LLC lifted its holdings in shares of LivaNova by 13.0% during the fourth quarter. Algert Global LLC now owns 118,713 shares of the company’s stock worth $5,498,000 after buying an additional 13,696 shares in the last quarter. Aristeia Capital L.L.C. bought a new stake in shares of LivaNova in the fourth quarter valued at about $3,395,000. AXA S.A. acquired a new position in shares of LivaNova in the fourth quarter valued at about $1,662,000. Finally, Jane Street Group LLC grew its stake in shares of LivaNova by 45.5% in the fourth quarter. Jane Street Group LLC now owns 193,826 shares of the company’s stock valued at $8,976,000 after acquiring an additional 60,613 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

LIVN has been the subject of a number of recent research reports. Needham & Company LLC reissued a “buy” rating and issued a $64.00 price objective on shares of LivaNova in a report on Tuesday, May 13th. The Goldman Sachs Group dropped their price target on shares of LivaNova from $64.00 to $55.00 and set a “buy” rating for the company in a research report on Monday, March 3rd. StockNews.com cut LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 8th. Robert W. Baird increased their price target on LivaNova from $55.00 to $61.00 and gave the stock an “outperform” rating in a research report on Thursday, May 8th. Finally, Stifel Nicolaus dropped their price objective on LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a report on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, LivaNova currently has an average rating of “Moderate Buy” and a consensus target price of $59.17.

LivaNova Stock Performance

Shares of LivaNova stock opened at $44.40 on Monday. The company has a 50 day moving average of $38.39 and a 200-day moving average of $44.81. LivaNova PLC has a 1-year low of $32.48 and a 1-year high of $62.04. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The company has a market cap of $2.42 billion, a PE ratio of 105.71 and a beta of 0.84.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.